Fractional Flow Reserve Proves Itself Early In St. Jude’s FAME II Study
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical’s fractional flow reserve technology gave stenting a significant enough edge in stable coronary disease patients that a monitoring board recommended stopping the study early because it would be unethical to continue to randomize patients to the optimal medical therapy control group.
You may also be interested in...
Medical Device Market & Industry Briefs, September 2012
Brief summaries of recent medtech market and industry developments. This month we cover results of St. Jude’s FAME II fractional flow reserve trial, a breakthrough technology for treating vascular occlusions, and analysis from START-UP magazine’s second annual Life Science Venture Capital Survey.
St. Jude’s FAME II FFR Study Successful, But Impact Is Debated
Final results from the firm’s FAME II trial show the benefits of fractional flow reserve technology as an aid to patient selection for cardiac stenting, but because no heart attack or mortality reduction was found, the significance of the data is disputed.
Research In Brief
Details from St. Jude's FAME II study on fractional flow reserve technology. Robot-assisted kidney surgery. More research news.